Voices
Maryam Lustberg
Maryam Lustberg/LinkedIn

Maryam Lustberg: Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer

Maryam Lustberg, Director Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared a post on LinkedIn:

“Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer

PFS 8.2 mo in pts with 1-2 prior endocrine therapy

Monotherapy SERD remains a good option for those tumors with endocrine sensitivity.”

Title: Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer

Authors: Hope S. Rugo, Virginia Kaklamani, Heather McArthur, Seth A. Wander, William Gradishar, Reshma Mahtani, Mark Pegram, Maryam Lustberg, Elyse Swallow, Jessica Maitland, Sebastian Kloss, Tomer Wasserman, Sara M. Tolaney

Read the Full Article.

Maryam Lustberg

cancer Elyse Swallow Heather McArthur Hope S. Rugo Jessica Maitland Mark Pegram Maryam Lustberg OncoDaily Oncology Reshma Mahtani Sara M. Tolaney Sebastian Kloss Seth A Wander Tomer Wasserman Virginia Kaklamani William Gradishar